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Previously, we identified an HBV binding factor (HBV-BF), a 50-kDa serum glycoprotein which interacts with HBV envelope
proteins and which is also located in the membrane of normal human hepatocyte (A. Budkowska et al. (1993) J. Virol. 67,
4316). Here we show that HBV-BF is a neutral metalloproteinase which shares substrate specificity and properties with a
newly described family of membrane type matrix metalloproteinases. HBV-BF treatment of the HBV resulted in the cleavage
of the N-terminal part of the middle HBV envelope protein at the pre-S2(136–141) amino acid sequence VRGLYF/L (containing
a single arginine cleavage site). HBV-BF affected the reactivity of the large HBV protein with pre-S1-specific MAbs, probably
inducing the conformational change of the pre-S1 domain. The HBV-BF-digested virus remained morphologically intact with
unchanged S antigenic determinants. The structural modifications of the viral envelope proteins induced by HBV-BF enabled
cell membrane attachment and viral entry into the T-lymphocyte. Both processes were blocked by the metalloproteinase
inhibitor 1,10 phenanthroline. Thus, the host-dependent proteolytic activation of the envelope proteins seems to be essential
for the HBV entry into the cell. HBV-BF under a membrane bound or a secreted form could be (one of) the molecule(s)
responsible for the HBV proteolytic activation. q 1997 Academic Press
INTRODUCTION ments of the viral genome, are located at the surface of
virions and of subviral particles. They may act as viral
The entry of enveloped viruses into their target cells
attachment proteins in the interaction of HBV with the
requires the binding of the virus to one or more cellular
membrane receptor(s) on the surface of the hepatocyte
receptor(s) and the fusion of the envelope with the target
(8, 9, 28). The S protein is probably fusogenic (37).cell membrane. In some cases the same molecule re-
The early stages of the HBV infection remain unknownsponsible for virus attachment can also mediate internal-
due to the failure to cultivate HBV in vitro. The majorization. For other viruses such as Sendai virus, influenza
target organ of HBV is the liver. Hepatocytes are appar-A virus, Newcastle disease virus, murine coronavirus,
ently the only cells susceptible and permissive to infec-human immunodefficiency virus type 1, and rotaviruses
tion, although viral antigens and DNA have been de-(14, 26) proteolytic cleavage of viral surface glycoproteins
tected in many extrahepatic tissues. Cellular componentsby host cell proteases is necessary for viral infection.
involved in the entry of HBV into its target cell have notThe cleavage results in the exposure of a hydrophobic
been identified and little is known about the biologicalstretch of amino acids which acts as the mediator of
bases of its restricted host range and tissue tropism.membrane fusion and determines tissue tropism of these
Various molecules have been described as candidatesviruses, especially if the virus utilizes ubiquitous mole-
for HBV receptors (7, 12, 28, 30, 42); however, there iscules as receptors.
no evidence that a particular component mediates pro-Hepatitis B virus (HBV) is a member of the hepadnavi-
ductive infection. Recent data have shown that peripheralrus family. It is composed of a 3.2-kb DNA genome, a
mononuclear cells of HBV-infected patients exhibit ad-nucleocapsid core and a viral envelope, containing three
sorbed viral particles but not the replicating virus (15),coterminal viral glycoproteins termed large (L), medium
thus raising the question of the presence of HBV recep-(M), and small (S). These HBV surface proteins are en-
tors on human lymphoid cells and the possibility of thecoded by a single open reading frame—gene S—com-
HBV entry into this type of cell.posed of the pre-S1, pre-S2, and S regions with alterna-
We have described in human serum a 50-kDa mole-tive translational initiation sites. The domains of the M
cule, called ‘‘HBV-binding factor’’ (HBV-BF) which inter-and L proteins, encoded by the pre-S1 and pre-S2 frag-
acts with the pre-S1 and pre-S2 epitopes of the viral
envelope (5). The immunochemical properties of this mol-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 14568 8261. E-mail: abudkow@pasteur.fr. ecule, its reactivity with the putative viral attachment pro-
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teins, and the localization of an antigenically related com- Superose 12 column (Pharmacia) and by SDS–PAGE. As
previously described (5) the purified HBV-BF was elutedponent in the membrane of the human hepatocyte sug-
gested that HBV-BF may be involved in the HBV entry from the HPLC column as a single peak of activity of a
molecular mass of 50 kDa, corresponding to a singleinto the cell. Here we show that HBV-BF displays the
properties of a member of recently described membrane- peak of protein (O.D. 0.2 1 1003). The trace amounts of
protein components of a molecular mass of 10 kDa ortype matrix metalloproteinase family (38) and induces
structural modifications of the viral envelope enabling less were eluted after HBV-BF peak and did not show
any reactivity with HBV envelope. No bands or only aattachment and internalization of HBV into the T-lympho-
cyte cell line. weak 50-kDa protein band could be detected in the puri-
fied HBV-BF preparation after SDS–PAGE under nonre-The proteolytic activation of the envelope proteins with
an enzyme identical or related to HBV-BF seems to be ducing conditions followed by a silver staining.
required for HBV entry into the cell. Proteolysis which
Determination of the inhibitory effect of HBV-BF ontriggers a conformational change of the HBV envelope
the binding of MAbs to the HBV envelope proteinsmight induce the exposure of the fusogenic sequence
necessary for the fusion of the viral envelope with the
Inhibition assays for detection of HBV-BF were carriedcell plasma membrane. Thus, the presence of this type
out as previously described (5). The assays were basedof enzyme in the active form in the membrane or in the
on the inhibition by HBV-BF of the binding of horseradishvicinity of the target cell could be determinant for this
(HRPO)-labeled MAbs to the pre-S1, pre-S2, and S regionprocess.
encoded epitopes on HBV or on recombinant m-HBsAg
particles. The wells of microtiter plates (Nunc, Roskilde,
MATERIAL AND METHODS
Denmark) were coated with HBV or m-HBsAg particles
at a concentration of 1 mg of protein per milliliter. TheCell culture
plates were overcoated with 1% bovine serum albumin –
The human T lymphoblastoma cell line CEM was cul- 0.05% Tween 20 in phosphate-buffered saline. Samples
tured in a RPMI 1640 medium (Gibco BRL) supplemented tested for HBV-BF activity were incubated for 2 hr at 377
with 10% of fetal bovine serum, 2 mM L-glutamine, 100 on HBV or m-HBsAg-coated plates and after washing the
units/ml of penicillin, and 100 mg/ml of streptomycin. The wells were incubated with HRPO-labeled MAbs and then
medium was changed three times a week. with o-phenylenediamine as a substrate. MAbs used in
the assay and their epitope specificity are detailed inHBV and recombinant HBsAg particles
Table 1. MAbs Ma18/7 (39) and E21/14 (22) were kindly
HBV particles were purified from the plasma of HBV provided by W. H. Gerlich, MAbs F124 (4), F376 (6, 26)
carriers by a sequence of ultracentrifugations as pre- 39-10 (6), and 5a-19 (6) were produced in our laboratory,
viously described (5). Recombinant HBsAg particles (m- MAbs 144 and 112 were kindly provided by J. P. Bour-
HBsAg) were produced in Chinese hamster DHFR0 ovary geois (Sanofi Diagnostics Pasteur) and MAb E6 (22) by
cells transfected with a plasmid encoding the pre-S re- B. Porstmann.
gion of the S gene of HBV and murine dihydrofolate re- The absorbance (A) values at 492 nm were measured
ductase (23). These particles contained three polypep- by ELISA in the linear range of the assay and the results
tides of a molecular mass of 22, 26, and 43 kDa corre- were expressed as percentage inhibition calculated as
sponding to the small (24 and 26 kDa) and the middle follows:
(34 kDa) envelope proteins. Polypeptides of 26 and 34
Percentage inhibitionkDa were glycosylated. Recombinant m-HBsAg particles
were purified by the producer and were kindly provided  A negative control 0 A test sample
A negative control 0 A positive control 1 100by R. Vinas (Pasteur Me´rieux).
The negative controls were at the absorbance valuesPurification of HBV-BF
1.6–1.9 and positive controls at 0.05 to 0.2.
HBV-BF was purified from human serum as previously
described (5). Globulins were precipitated from serum Biomolecular interaction analysis (BIA core) of the
with 50% ammonium sulfate, followed by ion exchange HBV-BF activity
chromatography (DE 52, Whatman) and gel permeation
with a series of three Sephacryl S200 columns (Phar- HBV or recombinant m-HBsAg particles were immobi-
lized on the sensor chip CM5 directly or by the intermedi-macia, Sweden). The final preparation was incubated
with insoluble rabbit antibodies to human IgG to remove ate of 39-10 MAb anti-HBs using the procedure de-
scribed by Jonsson et al. (13). The carboxylated dextrancontaminating IgG or its fragments.
The level of purity of HBV-BF was determined using matrix of the sensor chip was activated using N-hydroxy-
succinimide (NHS) and N-ethyl-N*-(3-diethylaminopropyl)high-performance liquid chromatography (HPLC) with a
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carbodiimide (EDC) (Pharmacia Biosensor, Uppsala, (10 mM EDTA 10 mM Tris–HCl, pH 7.8, 150 mM NaCl,
0.2% SDS) for 2 hr at 457. The samples were extractedSweden). The ligand 0 m-HBsAg particles (30 ml) at a
concentration of 100 mg/ml in a buffer, pH 5.0, were in- with phenol/chloroform, and the DNA was precipitated
with ethanol and resuspended in 20 ml of 10 mM Tris–jected followed by 30 ml of 1 M ethanolamine hydrochlo-
ride at pH 8.5, to deactivate the unreacted groups. Subse- HCl, pH 7.4, containing 1 mM EDTA. The samples were
then analyzed by PCR with oligonucleotide primersquently, 25 ml of the purified preparation of HBV-BF in
PBS were injected over the surface of the sensor chips. MD027 (nt position 1861–1880) and MD 031 (nt position
2286–2270) corresponding to the conserved sequencesAny change in the surface concentration resulting from
the interaction of HBV-BF with HBV or recombinant m- of the C gene.
The PCR products were separated by electrophoresisHBsAg particles was detected as an optical phenomenon
of the surface plasmon resonance (SPR) signal ex- in a 1.2% agarose gel containing ethidium bromide and
were analyzed by Southern blotting on a Hybond-N mem-pressed in resonance units (RU). The continuous display
of RU as a function of time was referred to as a senso- brane (Amersham, England). The plasmid (pCP10) con-
taining two complete head to tail copies of HBV genomegram. The effect of the action of HBV-BF on the immobi-
lized particles was investigated by incubation of the sen- (subtype ayw) cloned into pBR322 at the EcoRI site was
labeled with dUTP-fluorescein using the ECL randomsor chips with a series of MAbs directed to the pre-S
and S epitopes. priming kit (RPMN3040, Amersham) and used as a probe.
The hybridized fluorescein-labeled probe was detected
Analysis of the effect of proteinase inhibitors on HBV- on the blots with a horseradish peroxidase-labeled anti-
BF activity fluorescein antibody, and revealed by chemolumines-
cence (ECL, Amersham). Using this method, 0.01–0.001Inhibitors of different groups of proteases were mixed
with purified HBV-BF prior to incubation with recombinant fg/sample of cloned HBV DNA (pCP10) could be detected
corresponding to 15–150 copies of the genome.m-HBsAg or HBV. The protease inhibitors were: pep-
statin, leupeptin, E64, chymostatin, phenylmethanesulfo-
Detection of ccc DNAnyl fluoride (PMSF), antipain, and soybean trypsin inhibi-
tor (Behringer Mannheim Biochemicals); 1,10 phenan-
Covalently closed circular DNA (cccDNA) in extracts
throline, EDTA, phosphoramidon, and aprotinin (Sigma
of cultured cells was detected as previously described
Chemical Co.) and were used at concentrations listed in
(19). Briefly, DNA was extracted and precipitated as
Table 2. The effect of the inhibitor was expressed as
above and analyzed by PCR using two pairs of primers.
percentage of the residual HBV-BF activity measured by
The choice of primers was determined by the position
ELISA as compared to the activity of HBV-BF mixed with
of the minus strand gap between nucleotides 1823 and
PBS instead of inhibitor.
1834. The forward primer S/, 5* GGG AGT GGG CCT
CAG CCC GTT TCT CCT G-3* (nucleotides 643–669 ofInoculation of CEM-cells
S gene) and either reverse primer X0, 5*-GGA ACG GCA
Cells (1 1 107) were washed three times with the cell
GAC GGA GGG GAC GAG A-3* (nucleotides 1511–1484
culture medium without fetal calf serum. The cells were
of X gene) or reverse primer C0, 5*-ATG CCC CAA AGC
subsequently incubated for 1 hr (at 4 or 377) with 40 ml
CAC CCA AGG CAC AGC-3* (nucleotides 1903–1877 of
of HBV (corresponding to 44 pg of HBV DNA) or with the
gene C) were used.
same amount of HBV mixed with purified HBV-BF (8 mg
To prevent pairing between newly synthesized DNA
protein/ml). HBV-BF-treated and control samples were
strands initiated by primers C0 and S/ when RC-DNA
preincubated for 1 hr at 377 before inoculation of the
was the template, the three primers were designed to
cells. In some experiments, the HBV-BF inhibitor, 10 mM
hybridize above 727 (average Tm of 807) and were used1,10-phenanthroline, was included in the reaction mix-
in excess. The detection limits of this technique after
ture. The effect of HBV-BF on the envelope proteins was
Southern blot and hybridization for both pairs of primers
controlled by ELISA using pre-S-specific MAbs as de-
ranged from 0.1 to 1 fg/sample when the plasmid pCP10
scribed above. The inoculated cells were washed as
described above was used as a template (19).
above, transferred to a complete culture medium con-
taining 10% fetal calf serum, and grown at 377. In some Isolation of cell surface components
experiments the cells were subsequently digested with
0.5% trypsin to remove virus adsorbed onto the cell sur- Cell surface proteins were isolated by a modification
of the method of Maisner et al. (20). The cells were biotinface. Aliquots of inoculated cells were harvested for PCR
analysis at days 1 to 13. labeled, washed, and lysed in a buffer containing 1%
Triton X-100, 0.1% SDS, 1% DOC, 0.15% NaCl, and prote-
Detection of HBV-DNA in the inoculated cells ase inhibitors. The labeled components were isolated by
adsorption on insoluble streptavidin-agarose and sepa-Aliquots of inoculated cells (or cellular fractions) were
digested with 500 mg/ml of proteinase K in a lysis buffer rated by centrifugation.
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TABLE 1Isolation of nuclear and cytoplasmic fractions from
CEM cells Influence of HBV-BF on the Binding of MAbs
to the HBV Envelope ProteinsThe method described by Qiao et al. (36) was used
to separate nuclear fraction from cell membranes and Percentage
cytoplasm. The cells were washed three times with cold Solid phase Epitope recognized inhibition
antigen MAb (aminoacids) by HBV-BFPBS, centrifuged at 6000 rpm for 2 min, and the cell
pellets were resuspended in 200 ml of 0.5% NP-40, 1 mM
m-HBsAg (ay) F124 pre-S2 (120-126) 90–100EDTA, 150 mM NaCl in 10 mM Tris–HCl, pH 7.4. The Q19-10 pre-S2 (120-126) 90–100
suspension was mixed and incubated for 5 min at room F376 pre-S2 (133-145) 40–60
temperature to solubilize cell membranes and then cen- E6 pre-S2 (136-141) 40–60
39-10 a determinant of S protein 0–5trifuged as above. The pellet was considered as the ‘‘nu-
144 a determinant of S protein 0–5clei-enriched’’ fraction and the supernatant as the ‘‘cyto-
112 a determinant of S protein 0–5plasmic’’ fraction. The fractions were morphologically ex- m-HBsAg (ad) E21/14 pre-S2 (162-168) ad 0–2
amined under the light microscope after staining with
HBV (ay) F124 pre-S2 (120-126) 90–100hematoxylin. This analysis revealed the presence of solu-
E6 pre-S2 (136-141) 40–60ble components and no visible nuclei in the cytoplasmic Ma 18/7 pre-S1 (28-36) 80–100
fraction and a large amount of free nuclei and very few 5a-19 pre-S1 (36-43) 80–100
intact cells in the nuclei-enriched fraction. 39-10 a determinant of S protein 0–5
114 a determinant of S protein 0–5
122 a determinant of S protein 0–5HBV-BF analysis by zymography
HBV (ad) E21/14 pre-S2 (162-168) ad 0
Samples (0.1 ml) containing HBV-BF (8 ng of protein)
were solubilized in a buffer containing 10% glycerol, 1%
SDS–polyacrylamide gels copolymerized with 1 mg/mlSDS, and bromophenol blue. Electrophoretic migration
of gelatin as described above.was carried out on 7% SDS–polyacrylamide gels and
copolymerized with 1 mg/ml of gelatin or casein as pre- Western immunoblotting
viously described (11, 41). SDS was extracted with Triton
Specimens were solubilized in a buffer containing 2%
X-100 and the gel was incubated overnight at 377 in a
SDS, 5% 2-mercaptoethanol, 0.01% bromophenol blue,
reaction buffer containing 50 mM Tris–HCl, pH 7.4, 5
and 20% glycerol for 2 min at 1007. Proteins were sepa-
mM CaCl2 , and 5 mM ZnCl2 . To investigate the effect of rated on 5–15% polyacrylamide gradient gels and elec-
proteinase inhibitors: 50 mM 1,10 phenanthroline, 100
troblotted onto nitrocellulose. The membrane strips were
mM EDTA, 1 mM PMSF, or 2 mM N-ethylmaleimide
blocked overnight at 47 with 5% skim milk, washed, and
(NEM) were added to the reaction buffer. Gels were
let to react for 1 hr at room temperature with MAbs di-
stained with 0.5% Coomassie brilliant blue G250 in 30%
luted in 1% skim milk. The MAbs used for immunoblotting
methanol, and 10% acetic acid for 4 hr. This technique
included anti-pre-S1 MAb 5a-19 (6), anti-pre-S2 MAbs
detects clear bands, the cleaved (active) forms of en-
F124 (4), and E21/14 (22) and anti-HBs MAb H166 (25)
zymes as well as their inactive (uncleaved) precursors
reactive with all denatured HBV envelope proteins, kindly
(proenzymes) due to the exposition of the active site of
provided by L. T. Mimms.
the enzyme by conformational changes induced under
experimental conditions as demonstrated by Herron et Electron microscopy
al. (11). This process is not, however, considered as an Two-step staining procedure was used: 400-mesh
activation, where the cleavage of a propeptide results in grids coated with plastic-carbon films were placed onto
the exposition of the active, enzymatic site since the real a drop of virus suspension, dried with a filter paper, and
activation process can be evidenced by a decrease in finally floated on a drop of negative stain (1% phospho-
the molecular weight of the analyzed molecule. tungstic acid). The specimens were observed with a
JEOL JEM-1010 electron microscope.
Activation of MMP-2 by HBV-BF
RESULTS
Conditioned media from hepatic stellate cells, con-
Modification of the L and M envelope proteins bytaining a latent form of the matrix metalloproteinase-2 (1)
HBV-BFwere prepared as previously described (17, 41). Aliquots
of these preparations (15 ml) were incubated with 0.1, 1, To define the mode of action of HBV-BF on the enve-
lope proteins we analyzed the inhibitory activity of thisor 5 ml of HBV-BF (corresponding to 8, 80, or 400 ng of
protein), with or without proteinase inhibitors (10 mM molecule on the binding of MAbs directed to different
epitopes on the recombinant m-HBsAg and serum HBV1,10 phenanthroline, 10 mM EDTA, 1 mM PMSF, or 2
mM NEM) 6 hr at 377 and analyzed by zymography in 7% (Table 1). The first series of experiments with recombi-
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nant m-HBsAg as a solid phase antigen demonstrated creased of about 6–8 kDa after incubation with HBV-BF,
whereas the S and L HBV proteins remained unchangedthat the binding of MAbs F124 and Q 19-10 specific to the
N-terminal, pre-S2 epitopes (aa 120–126), was strongly (Fig. 1D).
All these data suggested that HBV-BF can be a protein-inhibited (90–100%) by HBV-BF. Binding of MAbs F376
and E6 reactive with the epitopes localized in the pre- ase cleaving the M protein within the pre-S2 sequence
in recombinant as well as in the viral particles. HBV-BFS2 (aa 133–145) sequence was only partially inhibited
(40–60%), whereas binding of MAb E21/14 specific to did not cleave the L protein, since the potential cleavage
sites in the pre-S2 domain are not accessible in the Lthe C-terminal pre-S2 sequence (aa 162–168) was not
blocked by HBV-BF. The reactivity of the S determinants protein (8). However, HBV-BF hampered the reactivity of
the pre-S-specific MAbs with the corresponding epitopesof HBsAg particles remained unchanged as evidenced
by the binding of three different anti-S-specific MAbs. in the L protein, suggesting that either a conformational
modification or blocking of the pre-S domains occurred.These results suggested that the interaction site of HBV-
BF with the pre-S2 domain is located in the central part Indeed, the large HBV protein of unchanged molecular
weight, reactive with pre-S1- and pre-S2-specific MAbsof the pre-S2 region (aa 133–145) corresponding to the
epitopes recognized by MAbs F376 and E6. was evidenced by Western blotting in HBV-BF-treated
HBV particles. The observed modifications did not con-Another series of experiments with complete virions
as the solid phase antigen showed that HBV-BF blocked cern the S protein domain since the conformational a
determinant of the HBV envelope remained immunologi-the binding of the pre-S2-specific MAbs F124 and E6 to
the viral particles in the same way as to the m-HBsAg cally unchanged and the electron-microscopic analysis
of the HBV-BF-digested virions showed their well-con-(Table 1). Interestingly, the binding of the MAb E21/14
specific to the C-terminal epitope of the pre-S2 domain of served structure (Fig. 2B) in comparison with the native
HBV (Fig. 2A).HBV was not inhibited but significantly enhanced (150–
230%) following incubation with HBV-BF. This observa- The proteinase activity of HBV-BF was further evidenced
by the real-time biospecific interaction analysis (BIA core).tion suggested a conformational change and exposition
of the C-terminal part of the pre-S2 domain. HBV-BF HBV or m-HBsAg particles were immobilized on the sensor
chips (Fig. 3A) and incubated with purified HBV-BF (Fig.blocked the binding of the two pre-S1 domain-specific
MAbs Ma18/7 and 5a-19 (80–100% inhibition), recogniz- 3B). Identical results were obtained for both systems involv-
ing m-HBsAg or HBV on the sensor chips: cleavage of theing pre-S1 (28 – 36) and pre-S1 (36–43) aa sequence,
respectively. The reactivity of the three different S region- immobilized components could be directly observed as a
release of the material from the sensor chip surface evi-specific MAbs remained unchanged.
The interaction of HBV-BF with the surface HBV antigens denced by a lowering sensogram baseline after injection
of HBV-BF (Fig. 3B). HBV-BF-treated HBV and m-HBsAgwas further analyzed by SDS–PAGE followed by immu-
noblotting with anti-pre-S antibodies (Fig. 1). The M HBV did not bind MAb F124, suggesting that the corresponding
epitopes were removed from the surface. MAb E6 boundprotein (gp34/gp36) was undetectable or only weakly
stained with the pre-S2-specific MAbs F124 after treatment weakly, whereas MAb 39-10 conserved its binding capacity
(data not shown). These observations confirmed the partialof both m-HBsAg particles and HBV with HBV-BF (Figs. 1A
and 1B), suggesting that this epitope was cleaved from the removal and stability of the corresponding epitopes, re-
spectively. Therefore, the results obtained with BIA coreM protein. It should be mentioned that the L protein is not
reactive with MAb F124 since this MAb selectively binds were consistent with those obtained with ELISA and con-
firmed HBV-BF to be a proteolytic enzyme, which cleavedto the pre-S2 (120–126) epitope glycosylated at the Asp
123 in the M protein, whereas there is no glycan linked to the M protein.
the corresponding epitope in the L protein (8, 10). In further
experiments a faster migrating 28-kDa band, corresponding Determination of the cleavage site in the M HBV
to a cleaved form of the M protein, was detected in the protein
HBV-BF-treated m-HBsAg using MAb E24/14 specific to the
C-terminal pre-S2 (162–168) epitope (Fig. 1C). A protein To determine the cleavage site of HBV-BF in the pre-
S2 domain, different anti-pre-S MAbs were reacted inband of the same molecular weight was detected in HBV-
BF-treated virions when MAb H166, reactive with a sequen- ELISA with m-HBsAg or HBV particles prior to their incu-
bation with HBV-BF to determine which of the pre-S-tial epitope of the S domain was used for immunoblotting
(Fig. 1D). specific MAbs could prevent the effect of HBV-BF. Most
of the pre-S2-specific MAbs (F124, Q-19/10, and E 21/In contrast, the L HBV protein (p39/gp41) of unchanged
molecular weight was evidenced by immunoblotting in 14) did not affect the reactivity of HBV-BF with the pre-
S2 domain; MAb F376, partially inhibited HBV-BF (aboutvirions preincubated with HBV-BF using anti-pre-S1 MAb
(5a-19). (Fig. 1B). Immunoblotting analysis of the native 50%), whereas MAb E6 completely (100%) blocked the
action of HBV-BF on the M protein. These results sug-and HBV-BF-treated virions with anti-S MAb H166 con-
firmed that the molecular mass of the M protein de- gested that HBV-BF cleaves the pre-S2 domain at or
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FIG. 1. Cleavage of the middle HBV-envelope protein by HBV-BF evidenced by Western blot. Recombinant m-HBsAg or HBV particles were
incubated with HBV-BF and subsequently subjected to electrophoresis and immunoblotting with MAbs anti-pre-S2 F124 (A and B), E21/14 (C), anti-
pre-S1 MAb 5a-19 (B), and anti-S MAb H166 (D). Lanes A, native, untreated HBV or recombinant m-HBsAg; lanes B, HBV or m-HBsAg treated with
HBV-BF. The cleaved form of the M protein of a molecular mass of 28 kDa is shown on C and D.
spatially close to the aa sequence pre-S2 (136–141) accessible for this MAb. The cleavage of the pre-S2 pro-
tein at the Arg 137 as a potential cleavage site and re-(VRGLYF/L) corresponding to the epitope recognized by
MAb E6 and containing arginine residue (Arg 137) (Fig. moval of 17 amino acids (including glycosylated Asp 123
residue) is in accordance with the decrease of molecular4). This cleavage (i) abolished the reactivity of MAb F124
with the N-terminal pre-S2 epitope (120–126), (ii) partially mass of the M-HBV protein of about 6–8 kDa observed
by Western Blotting.blocked the reactivity of the antibodies to the central
part of the pre-S2 domain (133–145), (iii) increased the
HBV-BF is a neutral metalloproteinasereactivity of the MAb E21/14 with a corresponding C-
terminal epitope pre-S2 (162–168), which probably be- To investigate what type of proteinase is HBV-BF we
studied the effect of various proteinase inhibitors on thecame exposed on the surface of viral particles and better
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FIG. 2. Morphology of HBV-BF-digested virions used for inoculation of the CEM cells. Negatively stained preparation of the native virus (A) and
virus digested with HBV-BF (B). Bars correspond to 100 nm.
reactivity of HBV-BF. As shown in Table 2, the interaction HBV-BF shows the properties of a matrix
metalloproteinaseof HBV-BF with the two pre-S domains of HBV was unaf-
fected by inhibitors of aspartic proteinases, serine pro-
Zymography analysis showed that HBV-BF migrated inteinases, and cysteine proteinases. In contrast, the effect
SDS–PAGE as a 50-kDa band capable of degrading gel-of HBV-BF on both M and L proteins was abolished by
atin and casein, two typical substrates of the matrix me-two metalloproteinase inhibitors: EDTA and 1,10 phenan-
talloproteinases (Fig. 5). Both activities were inhibited bythroline, but was unaffected by phosphoramidon, which
EDTA and 1,10 phenanthroline (partially for gelatin andis a specific inhibitor of bacterial metalloproteinases and
completely for casein), whereas other proteinase inhibi-does not inhibit matrix metalloproteinases.
tors such as PMSF or NEM did not influence HBV-BFThe optimum pH for the reactivity of HBV-BF was in
activity.the neutral range and rapidly decreased at the low as
HBV-BF was further incubated with conditioned me-well as at basic pH values (showing 30% of activity at
dium from hepatic stellate cells which secrete a latentpH 5.0 until complete inactivation at pH 3.5 and 50%
form of a matrix metalloproteinase 2 (MMP-2, gelatinaseactivity at pH 9.5). This feature, as well as the sensitivity
A, EC 3.4.24.24) (17, 41) and the mixtures were analyzedto the action of chelating agents, suggested HBV-BF to
be a member of the neutral metalloproteinase family. by zymography. The latent form of MMP-2 (proenzyme)
FIG. 3. Proteolytic activity of HBV-BF evidenced by a real time Biospefic Interaction Analysis (BIA core). (A) Sensogram showing immobilization
of recombinant m-HBsAg particles on a sensor chip. (a) The pulse of NHS and EDC gives an increase in the SPR signal due to the change in the
bulk refractive index. (b) Corresponds to the injection of 30 ml of m-HBsAg and (c) to the injection of ethanolamine to deactivate the sensor chip
surface. The amount of immobilized particles corresponds to 8264 RU (d). (B) HBV-BF (25 ml) was subsequently injected twice (a and b) over the
sensor chip surface. The baseline difference between the beginning and the end of the sensogram after the first injection indicates cleavage of
the portion of the surface-bound m-HBsAg, corresponding to 400 RU.
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FIG. 4. Localization of the cleavage site of HBV-BF in the pre-S2 domain of the M HBV protein. Linear maps of the pre-S2 sequences of ayw and
adw2 subtypes are presented. Numbers indicate aminoacids along the M protein. Epitopes recognized by pre-S2 specific MAbs are shown in
boldface types. The cleavage site of HBV-BF corresponds to the VRGLYF/L epitope recognized by MAb E6.
appeared as a clear band of a molecular mass of 66 to prevent endocytosis, which usually occurs above 107,
kDa, as previously described (41), HBV-BF as a 50-kDa and to ensure that the virions remained bound and intact
band and an additional band of a molecular mass of 62 during the incubation and washing procedure. Control
kDa corresponded to a cleaved (activated) form of experiments were performed at 377. After the binding and
MMP-2. The 62-kDa band was detected in a dose-de- washing steps the cells were transferred to a complete
pendent manner following treatment with increasing medium and grown at 377 up to 13 days after inoculation.
concentrations of HBV-BF (Fig. 6A). The activation of DNA was extracted from the cells and assayed for HBV
MMP-2 by HBV-BF was inhibited by EDTA, 1,10 phenan- sequences by PCR. In studies of HBV internalization the
throline, and partially by PMSF (Fig. 6B). Serine protein- washing steps were followed by trypsin digestion to elim-
ase inhibitor NEM failed to inhibit the processing of inate any bound virus.
MMP-2 by HBV-BF. All these results showed that HBV- The extracts tested up to 13 days after inoculation
BF has the enzymatic properties of a typical matrix me- (either at 4 or 377) with HBV-BF-digested virus showed
talloproteinase. intense HBV-DNA bands corresponding to the amplified
product of 430 bp (Fig. 7A). In contrast no HBV-DNA
Activation of the envelope proteins by HBV-BF was detected in the extracts prepared from CEM-cells
enables adsorption and entry of HBV into the cell inoculated with the native, untreated HBV when tested
from days 1 to 13 postinoculation.Human peripheral blood mononuclear cells can ad-
To investigate whether modifications of the viral enve-sorb viral particles (15, 33, 34), but seem to be refractory
lope proteins by HBV-BF influence either viral attachmentto HBV infection (15). Therefore we addressed the ques-
or internalization, subcellular components were isolatedtion whether the structural modifications induced by
and obtained fractions assayed for the presence of HBV-metalloproteinase (HBV-BF) treatment can facilitate inter-
DNA by PCR. The cell surface fraction isolated from thenalization and/or replication of HBV in T-lymphocytes.
cells inoculated with metalloproteinase (HBV-BF)-digestedCEM-cells were inoculated with either the native or HBV-
BF-digested virus. The adsorption was carried out at 47 virus and harvested on day 2 postinoculation showed a
TABLE 2
Effect of Protease Inhibitors on the Interaction of HBV-BF with Pre-S Epitopes
Percentage HBV-BF activity
Proteinase group Inhibitor (a) (b)
Aspartate proteinases Pepstatin (1 mM) 95 96
Cysteine proteinases Leupeptin (100 mM) 92 94
E 64 (50 mM) 93 96
Chymostatin (100 mM) 96 96
Serine proteinases PMSF (1 mM) 98 96
Soybean trypsin inhibitor (100 mg/ml) 95 98
Aprotinin (0.6 mM) 94 95
Metalloproteinases EDTA (10 mM) 0 0
1,10 phenantroline (5 mM) 0 0
Phosphoramidon (600 mM) 94 97
Trypsin, papain, plasmin Antipain (120 mM) 96 98
Note. Purified HBV-BF was incubated with HBV particles coated on the solid phase without (control sample) or with the indicated proteinase
inhibitors. The results are expressed as percentage of residual activity of HBV-BF measured by inhibition ELISA with peroxidase-labeled (a) anti-
pre S1 Ma 18/7 and (b) anti-pre-S2 F124 MAbs as described under Material and Methods.
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to cultivate HBV in vitro suggest that the mechanisms of
natural HBV infection may require several factors for viral
binding, penetration, and transport into an adequate cel-
lular compartment. The receptors present on nonsuscep-
tible cells may function in focusing the virus onto the cell
membrane. Other factors present only in, or in the vicinity
of the target cell, would be required for subsequent steps
of infection, such as internalization and intracellular
transport of the virus to the cell nucleus where replication
starts.FIG. 5. Analysis of HBV-BF activity by zymography on gelatin and
casein gels. The gels were incubated overnight at 377 with reaction In this study we characterized HBV-binding factor, the
buffer containing or not inhibitors as described under Materials and molecule previously found in hepatocyte membranes and
Methods. Proteolytic activity was detected as a 50-kDa band. Lane 1, under a soluble 50-kDa form in normal human serum.no inhibitor added; lane 2, NEM; lane 3, PMSF; lanes 4 and 5, EDTA
HBV-BF is a member of the neutral metalloproteinaseand 1,10 phenanthroline, respectively, added to the reaction buffer.
family and displays the substrate specificity and the prop-
erties of a matrix metalloproteinase. HBV-BF modified
strong 430-bp band of HBV-DNA (Fig. 7B). No bands could the structure of the envelope proteins and enhanced the
be observed in the membrane fraction from the cells inocu- capacity of HBV to bind and enter into a T-lymphocyte
lated with the native HBV, and only weak bands were cell line. First, HBV-BF cleaved the M envelope protein
observed in the membrane fraction from the cells inocu- in the pre-S2 sequence. Cleavage resulted in (i) the de-
lated with the virus treated with HBV-BF in the presence crease of a molecular mass of the M protein of about 6
of 1,10 phenanthroline. These results showed that the ac- kDa, (ii) disappearance of the binding of the N-terminal
tion of HBV-BF enhances viral binding to the cell surface pre-S2 antibodies, (iii) reduction of the binding of the
and that this process is susceptible to a specific metallo- MAbs directed to the central part of the pre-S2 domain,
proteinase inhibitor, 1,10 phenanthroline. Furthermore, and (iiii) increase of the binding of C-terminal MAbs due
HBV-DNA bands were detected up to day 13 in both cyto- to the exposition of the corresponding epitopes. Cleav-
plasmic and nuclear fractions from cells inoculated with age of the M protein by HBV-BF was completely blocked
HBV-BF-digested virus, whereas no, or only trace amounts by metalloproteinase inhibitors, but also by MAb E6 spe-
of HBV-DNA, were found in fractions isolated from the cells
inoculated with the native virus (Fig. 7C). Therefore, HBV-
BF treatment apparently facilitated not only attachment to
the cell surface, but also viral internalization. This process
was also inhibited by 1,10 phenanthroline, confirming the
role of the metalloproteinase digestion in this event.
The cell extracts were also tested for the presence of
covalently closed, circular HBV-DNA (ccc-DNA) by the
strand-specific PCR. No amplification product was ob-
tained with the ccc-DNA-specific primers, although the
HBV-DNA signal did not decline with the time in the cell
culture inoculated with HBV-BF-digested virus. Thus, the
HBV DNA was exclusively in the RC form and there was
no evidence for HBV replication in this type of cell.
DISCUSSION FIG. 6. (A) Activation of MMP-2 by HBV-BF. Conditioned medium of
hepatic stellate cells containing a latent form of MMP-2 of a mol. mass
of 66 kDa was incubated with 8, 80, and 400 ng of the HBV-BF prepara-Several reports have suggested that the pre-S region
tion for 6 hr at 377 (lane 1, 2, and 3, respectively). The mixtures wereencoded protein domains of HBV envelope are responsi-
subsequently submitted to gelatin zymography analysis. The 62-kDable for attachment of HBV to cellular receptors (8, 9,
band corresponds to the cleaved form of MMP-2 and 50-kDa band to
28, 33, 34). The major S protein might have a potential HBV-BF. Lanes 4, 5, and 6 represent control samples containing 8, 80,
fusogenic activity, since the 23 N-terminal amino acids and 400 ng of HBV-BF, respectively, incubated in the same conditions in
the absence of conditioned medium. (B) Inhibition of MMP-2 activation.show a high degree of homology with fusogenic peptides
Conditioned medium of hepatic stellate cells containing a latent formof other viruses and are conserved among different HBV
of MMP-2 (66 kDa, lane 1) was incubated with 40 ng of the HBV-BFantigenic subtypes and within the hepadnavirus family
preparation for 6 hr at 377 without (lane 2) or in the presence of protein-
(37). The attachment of the HBV to various cells of human ase inhibitors (EDTA, lane 3; 1,10 phenanthroline, lane 4; NEM, lane
origin, which are not susceptible to infection has been 5; and PMSF, lane 6). Subsequently, the mixtures were submitted to
gelatin zymography analysis.demonstrated (29). This observation and the impossibility
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FIG. 7. (A) Detection of amplified HBV-DNA on day 8 in DNA extracts from cells inoculated with the virus digested with HBV-BF. CEM-cells (107)
were incubated either with 40 ml of HBV (40 pg of HBV DNA) or with the same amount of the virus preincubated with HBV-BF (8 mg of protein) as
described under Materials and Methods. The cells were subsequently trypsin digested, transferred to complete medium, and grown at 377. Aliquots
of cells were harvested for PCR analysis. Lanes 1 and 2 represent extracts of the cells inoculated with native HBV, lanes 3 and 4 extracts from
cells inoculated with HBV-BF-digested virus (lanes 2 and 4 represent 10-fold dilutions of the extracts analyzed in lanes 1 and 3, respectively). (B)
Detection of amplified HBV-DNA on day 2 in the membrane fraction isolated from cells inoculated with the metalloproteinase-digested virus.
Biotinylated surface proteins of CEM-cells inoculated with HBV, HBV digested with HBV-BF, or HBV pretreated with HBV-BF in the presence of
inhibitor (10 mM 1,10 phenanthroline) were isolated on streptavidin-agarose and the presence of HBV-DNA determined by PCR. (C) Detection of
amplified HBV-DNA on day 13 in the ‘‘cytoplasmic’’ and ‘‘nuclear’’ fractions isolated from CEM-cells inoculated with the native or with metalloproteinase-
digested HBV. The inoculation was carried out at either 4 or 377. HBV-BF inhibitor, 10 mM 1,10 phenanthroline.
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cific to the pre-S2 (136–141) epitope, suggesting that the activation of MMP-2 produced by hepatic stellate cells,
via plasma membrane-dependent mechanism (41).VRGLYF/L sequence is the cleavage site of HBV-BF in the
pre-S2 domain. This aa sequence contains the arginine This process is inhibited by EDTA and can therefore
be due to the metalloproteinase activity related to HBV-residue (Arg 127) and corresponds to a monobasic cleav-
age site present in other viral glycoproteins activated by BF, in accordance with our previous report showing
the localization of a component related to the solubleenzymes secreted from epithelial cells (14).
Moreover, HBV-BF hampered the reactivity of the pre- serum HBV-BF in the membranes of normal human
hepatocytes (5). The membrane-type matrix metallo-S-specific MAbs with the corresponding epitopes on the
L HBV protein. Since (i) this effect was prevented by proteinases exist also as HBV-BF in both membrane
bound and soluble, truncated forms of a molecularmetalloproteinase inhibitors and (ii) the intact L protein
could be evidenced by Western blot, it is conceivable mass of about 50 kDa (2, 31).
Our findings are consistent with recently publishedthat cleavage of the M protein by HBV-BF affected the
conformation of the large HBV protein. The HBV-BF-di- data by Lu et al. (18), who showed that HBV digested
with streptococcal V8 protease can efficiently infect thegested virus remained morphologically unchanged and
conserved its intact conformation-dependent S domain human hepatoblastoma cell line HepG2, refractive to in-
fection with native HBV. The authors suggested that thereactivity. Whether all these structural changes induced
by HBV-BF exposed potential N-terminal fusogenic se- lack of the suitable fusion-activation protease could be
responsible for the lack of susceptibility of this cell linequence of HBV-S protein is at present under investiga-
tion. to HBV infection. We therefore believe that the host-de-
pendent proteolytic activation of the virus contributes toThe human CD4/ T-lymphocyte cell line, CEM only
weakly bound native HBV and much more efficiently re- the entry of HBV into the cell. This mechanism would
implicate a fusogenic process presumably through a cellcombinant S,L* HBsAg particles composed of the major
S protein and of a truncated L* protein containing pre- surface interaction with the newly exposed sites of the
viral envelope. A neutral metalloproteinase identical orS1 (12–52) and pre-S2 (133–145) aa sequences (32) as
previously demonstrated by our group by immunofluores- related to HBV-BF is a good candidate for the enzyme
involved in the proteolytic activation which can be ofcent techniques (35). In this study the CEM cells did not
(or very weakly) adsorb and internalize the native virus, importance for the spread of HBV infection. The availabil-
ity of the activating proteinase in a membrane-bound orin contrast with the metalloproteinase (HBV-BF)-digested
virions. Therefore, the proteolytic activation of the enve- secreted form might be determining for HBV host range
and/or tissue tropism. Metalloproteinases are particu-lope proteins by HBV-BF enabled HBV binding to the cell
surface and viral entry into the cell. larly abundant at the apical surface of the epithelial cells
in the digestive and respiratory tracts and have beenThe substrate specificity and other enzymatic prop-
erties of the HBV-BF suggested that this molecule is a reported to be involved in the entry of other mammalian
viruses into cells (43).member of the matrix metalloproteinase (MMP) family.
MMPs are zinc requiring matrix-degrading enzymes The conformational changes induced by exposure to
low pH provide an efficient mechanism of entry of manywhich include collagenases, gelatinases, and stromel-
ysins, all of which are involved in the physiological as pH-dependent viruses (21). A number of other enveloped
viruses do not require exposure to acid pH for entry andwell as pathological remodeling of the extracellular
matrix (3). MMPs are secreted as catalytically latent a protease might function as a fusion trigger for these
pH-independent viruses (21). The activity of HBV-BF wasforms (zymogens). Their activity is tightly controlled by
mechanisms of proteolytic activation and modulated highest at neutral pH, and sharply decreased with acid
pH. Moreover, the metalloproteinase-digested virusby tissue inhibitors of matrix metalloproteinases in the
pericellular and extracellular environments. (3). Two could enter the cell without exposure to low pH. There-
fore HBV may also in vivo enter the cell by a pH-indepen-collagen degrading enzymes MMP-1 and MMP-2 were
detected in normal and fibrosis livers (24). Recently, dent mechanisms; e.g., by direct fusion between the viral
envelope and the plasma membrane.new members of this family, the membrane-associated
ectoenzymes were discovered and named ‘‘the mem- The detection of viral antigens and HBV DNA in periph-
eral blood mononuclear cells during the natural coursebrane-type matrix metalloproteinases’’ (MT-MMP-1, -2,
and -3) due to an additional transmembrane domain of infection raises the question whether the viral replica-
tion can take place in this type of cell (15, 16). In our(2, 31, 38). Particular attention has been focused on
the ability of some MT-MMPs to induce processing of studies we did not find in the inoculated cells the cova-
lently closed, circular DNA (ccc-DNA), the form of thethe MMP-2 zymogen to its activated form (gelatinase)
(38). The substrate specificity of the HBV-BF and its HBV genome considered as the evidence of viral replica-
tion, although the same viral preparation under the samecapacity to activate MMP-2 suggest that this molecule
can also be a membrane-located enzyme. Indeed, it experimental conditions was infectious in a primary cul-
ture of normal human hepatocytes (P. Gripon, personalhas been recently shown that hepatocytes induce the
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